Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Buy" by Brokerages

Key Points

• Autolus Therapeutics PLC has received an average recommendation of "Buy" from five research firms, with a target price set at $9.12.
• Significant investment activity includes a 2,891.7% increase in ownership by Bank of America Corp DE, now holding over $2.2 million worth of shares.
• The company reported quarterly earnings of ($0.18) per share, which beat expectations and was accompanied by revenue of $13.5 million.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has been assigned an average recommendation of "Buy" from the five research firms that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $9.12.

A number of research analysts have recently weighed in on the stock. Wells Fargo & Company reduced their target price on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Wall Street Zen upgraded Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Finally, Needham & Company LLC reissued a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, July 21st.

Institutional Investors Weigh In On Autolus Therapeutics

Large investors have recently added to or reduced their stakes in the company. Marex Group plc bought a new position in Autolus Therapeutics during the second quarter worth about $28,000. Bank of America Corp DE lifted its stake in shares of Autolus Therapeutics by 2,891.7% during the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company's stock valued at $2,223,000 after buying an additional 942,540 shares in the last quarter. Armistice Capital LLC boosted its holdings in Autolus Therapeutics by 9.1% in the 2nd quarter. Armistice Capital LLC now owns 12,000,000 shares of the company's stock worth $27,360,000 after buying an additional 1,000,000 shares during the period. TFG Asset Management GP Ltd grew its stake in Autolus Therapeutics by 10.5% in the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company's stock valued at $21,660,000 after buying an additional 900,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company's stock valued at $88,000 after acquiring an additional 11,289 shares during the period. Hedge funds and other institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Price Performance

Shares of Autolus Therapeutics stock opened at $1.37 on Wednesday. The firm has a market cap of $364.61 million, a PE ratio of -1.63 and a beta of 1.87. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $5.00. The stock has a fifty day moving average price of $2.10 and a 200-day moving average price of $1.84.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.06. The company had revenue of $13.50 million for the quarter, compared to the consensus estimate of $12.92 million. As a group, equities analysts anticipate that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.